DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1939)

Renal Cell Carcinoma | Landscape & Forecast | Disease Landscape & Forecast

Renal Cell Carcinoma | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Building on the success of Bristol-Myers Squibb / Ono Pharmaceutical’s PD-1 inhibitor, Opdivo, in the recurrent renal cell carcinoma (RCC) setting, combination regimens that include immune checkpoint inhibitors, including Opdivo plus Yervoy, look set to revolutionize the treatment of advanced disease. Angiogenesis inhibitors remain a key feature in RCC treatment with Exelixis /Ipsen’s Cabometyx joining Pfizer’s Sutent and Novartis’s Votrient as a first-line treatment. The entry and increased market share of Cabometyx and Opdivo in this setting is beginning to shift Pfizer’s Inlyta, the combination of Eisai’s Lenvima / Kisplyx with Novartis’s Afinitor, and single-agent mTOR inhibitors to later lines. Furthermore, following Sutent’s approval for high-risk early-stage (stage I-III) patients in the United States, multiple immune checkpoint inhibitors are also anticipated to transition into early-stage treatments. With the highly competitive RCC market becoming increasingly fragmented, the developer of an efficacious therapy could reap high commercial rewards.

Questions Answered:

  •  How large are the early-stage and advanced or metastatic drug-treatable populations? Will drug-treatment rates change over time?
  • How is RCC currently treated, and what are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • Who are the key players developing combination therapies for RCC? How will these combination regimens be differentiated, and which look most promising?
  • Which emerging therapies do we forecast to enter the each RCC market segment? What uptake and sales are these therapies anticipated to secure?

Product Description

Disease Landscape & Forecast  provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: Twenty country-specific interviews with thought leaders (medical oncologists and urologists).

Key companies: Bristol-Myers Squibb/Ono Pharmaceutical, Merck & Co./MSD, Exelixis/Ipsen, and Pfizer.

Key drugs: Opdivo, Keytruda, Cabometyx, and Inlyta.

Population segments in market forecast: Early-stage (stage I-III) renal cell carcinoma, first-line advanced or metastatic renal cell carcinoma, second-line advanced or metastatic renal cell carcinoma, third-line advanced or metastatic renal cell carcinoma, and fourth-line advanced or metastatic renal cell carcinoma.

Emerging therapies: Phase III: 8 drugs; Phase II: 18 drugs; coverage of select Phase I and preclinical products.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • March 2019
      • December 2018
      • October 2018
      • July 2018
      • May 2018
      • March 2018
      • November 2017
      • July 2017
      • June 2017
      • February 2017
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Renal Cell Carcinoma?
        • What Factors Are Constraining the Market for Renal Cell Carcinoma?
      • Segment-Specific Trends
        • Early-Stage (Stage I-III) Renal Cell Carcinoma
        • First-Line Advanced or Metastatic Renal Cell Carcinoma
        • Second- and Later-Line Advanced or Metastatic Renal Cell Carcinoma
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Pathophysiology
        • Staging and Classification
        • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution of Renal Cell Carcinoma
        • Recurrent Incident Cases of Renal Cell Carcinoma
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Immune Checkpoint Inhibitors
        • Angiogenesis Inhibitors
        • mTOR Inhibitors
      • Medical Practice
        • Early-Stage Renal Cell Carcinoma: Stages I-III
        • First-Line Advanced or Metastatic Renal Cell Carcinoma: Stage IV
        • Second-Line Advanced or Metastatic Renal Cell Carcinoma
        • Third- and Fourth-Line Advanced or Metastatic Renal Cell Carcinoma
        • Treatment Guidelines
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Renal Cell Carcinoma
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Renal Cell Carcinoma
        • Immune Checkpoint Inhibitors
        • Angiogenesis Inhibitors
        • Cytokines
        • Histone Deacetylase Inhibitors
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Renal Cell Carcinoma
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecasting Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Renal Cell Carcinoma Bibliography

Already a Client? Log in to access this report.

  • Pub Date: March 2019
  • Author(s): Joshua Dawkins, M.Pharmacol., PhD; Ema Rodrigues, DSc, MPH; Mudasir Khan, M.P.H
  • Joshua Dawkins, , is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr. Dawkins obtained his doctorate in molecular biology at the Barts Cancer Institute, Queen Mary University of London, where he investigated the roles of epigenetic histone modifiers in pancreatic ductal adenocarcinoma. Dr. Dawkins also holds a Master of Pharmacology degree awarded by the University of Bath, and completed a one-year professional placement within the oncology team at MedImmune.

  • Ema is an epidemiologist with expertise in forecasting incident and prevalent populations within oncology, as well as some cardiovascular indications such as venous thromboembolism. She has significant experience with statistical methods such as multivariate linear regression, conditional logistic regression, principal components analysis, mixed models, hierarchical modeling, and path analysis to account for the complex relationships among various predictors of health outcomes, particularly correlated variables. She completed her master’s and doctoral degree (MPH, ) in Environmental Health at Boston University School of Public Health, where she worked on projects investigating significant predictors of various health outcomes including central nervous system cancer, cognitive function, and birth outcomes.              

  • Mudasir works as an associate epidemiologist within the epidemiology team at Decision Resources Group. He specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio. Mudasir holds a masters in public health specializing in epidemiology from TISS, Mumbai.

Purchase Report

Recent reports:
You may also be interested in: